TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors

Phase 2

Terminated

• Conditions: Non-Malignant Hematologic Disorders
• Interventions: Drug: Melphalan; Drug: Thiotepa; Drug: Clofarabine; Drug: Fludarabine; Drug: Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®); Procedure: CliniMACS reagents

• Registration Number: NCT03615144
• Lead Sponsor: Memorial Sloan Kettering Cancer Center

Brief Summary

The purpose of this study is to find out if removing a specific type of white blood cell (called alpha beta T-cell) that help make up the transplant donor's stem cells can improve results of blood stem cell transplant for the participant's disease.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2018-07-23
• Study First Submitted: 2018-07-30
• Study First Submitted QC: 2018-07-30
• Study First Posted: 2018-08-03
• Status Verified: 2020-11
• Primary Completion: 2020-11-13
• Study Completion: 2020-11-13
• Results First Submitted: 2021-02-05
• Results First Submitted QC: 2021-02-05
• Results First Posted: 2021-02-24
• Last Update Submitted: 2021-03-01
• Last Update Posted: 2021-03-24

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 1

Inclusion Criteria

• Lethal disorders of Hematopoiesis correctable by transplant for which Alpha βeta T-cell and CD-19 depleted allogeneic hematopoietic stem cell transplantation is indicated including:

• Sickle cell disease (HbSS, HbSC, HbSB0 thalassemia, HbSB+, HbSD, HbSE) with at least one of the following criteria (Walters et al):

  1. Cerebrovascular accident lasting longer than 24 hours
  2. Impaired neuropsychological function with abnormal brain MRI/MRA
  3. Recurrent hospitalizations (>2 episodes/year over several years) or exchange transfusions for acute chest syndrome
  4. Recurrent priapism
  5. Stage I or II sickle chronic lung disease
  6. Sickle cell nephropathy (moderate to severe proteinuria or glomerular filtration rate 30-50% of predicted normal value for age)
  7. Bilateral proliferative retinopathy with major visual impairment in at least one eye
  8. Osteonecrosis of multiple joints
  9. Red cell alloimmunization during chronic transfusion therapy

• Thalassemia major with at least one of the following criteria:

  1. Age <16 years
  2. Available HLA-identical sibling
  3. Red blood cell transfusion dependency
  4. Lucarelli class 1 or 2 risk status (i.e. with only 0-2 of the following factors: hepatomegaly, portal fibrosis, or poor response to chelation therapy)
  5. Recurrence of disease after previous stem cell transplant

• Bone Marrow Failure Syndromes:

  1. Aplastic anemia refractory to immunosuppressive therapy
  2. Diamond Blackfan Anemia refractory to conventional therapy
  3. Shwachman-Diamond Syndrome
  4. Severe Congenital Neutropenia
  5. Congenital Amegakaryocytic Thrombocytopenia
  6. Thrombocytopenia Absent Radii syndrome
  7. Other marrow failure disorders not otherwise specified

• Autoimmune cytopenias refractory to all conventional treatments

  1. Autoimmune hemolytic anemia
  2. Immune thrombocytopenia
  3. Evan's syndrome
  4. Pure red cell aplasia

• Histiocytic disorders:

  1. Hemophagocytic lymphohistiocytosis
  2. High risk, recurrent or refractory Langerhans cell histiocytosis
  3. Secondary HLH

Subject Inclusion Criteria:

• Recipient's age birth to < 70 years old
• Patients must have adequate organ function measured by:
• Cardiac: asymptomatic or if symptomatic then LVEF at rest must be ≥ 50% and must improve with exercise.
• Hepatic: < 3x ULN AST and ≤ 1.5 mg/dl total serum bilirubin, unless there is congenital benign hyperbilirubinemia or if the hyperbilirubinemia is directly caused by the disease in which the patient is receiving a transplant for. Patients with higher bilirubin levels due to causes other than active liver disease are also eligible with PI approval e.g. patients with PNH, Gilbert"s disease or other hemolytic disorders.
• Pulmonary: asymptomatic or if symptomatic, DLCO ≥ 50% of predicted (corrected for hemoglobin).
• Renal: serum creatinine ≤1.5x normal for age. If serum creatinine is outside the normal range, then CrCl > 70 mL/min/1.73m2 (calculated or estimated) or GFR (mL/min/1.72m2) >30% of predicted normal for age.
• Normal GFR in Children and Young Adults.

Donor Inclusion Criteria:

• Each donor must meet criteria outlined by institutional guidelines and be medically eligible to donate according to NMDP (or equivalent donor search organization) criteria including testing for antibodies to Human TLymphotrophic Virus Types I & II (Anti-HTLV-I/II) and screening for West Nile Virus, Creutzfeldt-Jakob disease and Zika.
• Pediatric donors should weigh ≥ 25.0 kg, have adequate peripheral venous catheter access for leukapheresis or must agree to placement of a central catheter.
• Donor should be healthy and agree to receive G-CSF followed by donation of peripheral blood stem cells.
• Donors must agree to anesthesia and marrow donation (in cases of inadequate PBSC collection).
• Related or unrelated donors who are 7/8 or 8/8 HLA-antigen matched for haplotypes A, B, C, DRB1 OR Related donors who are 4-6/8 HLA-antigen matched.

Subject

Read More

Exclusion Criteria

• Female patients who are pregnant or breast-feeding
• Active viral, bacterial or fungal infection
• Patient seropositive for HIV-I/II; HTLV-I/II
• Karnofsky (adult)/Lansky (pediatric) < 70%
• Inherited DNA repair deficiency: Fanconi Anemia and Dyskeratosis Congenita. These are presently undergoing transplantation based on a multi-center protocol
• Patients with Thalassemia major with Pesaro risk score >II
• Inherited metabolic disorders: Hurler Syndrome, Sly syndrome (MPSVIII), α-Mannosidosis, X- ALD, Osteopetrosis

Donor Exclusion Criteria:

• Donors who are seropositive for HIV-I/II or HTLV-I/II and female patients who are pregnant or breastfeeding will not be eligible for this study.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Melphalan/Thiotepa/Clofarabine	Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)	Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
Melphalan/Thiotepa/Clofarabine	CliniMACS reagents	Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
Melphalan/Thiotepa/ Fludarabine	Melphalan	Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
Melphalan/Thiotepa/ Fludarabine	Thiotepa	Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
Melphalan/Thiotepa/ Fludarabine	Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)	Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
Melphalan/Thiotepa/ Fludarabine	CliniMACS reagents	Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
Melphalan/Thiotepa/Clofarabine	Melphalan	Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
Melphalan/Thiotepa/Clofarabine	Thiotepa	Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
Melphalan/Thiotepa/Clofarabine	Clofarabine	Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
Melphalan/Thiotepa/ Fludarabine	Fludarabine	Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.

Primary Outcome Measures

Name	Time	Method
Overall Survival (OS)	2 years	Overall survival is defined as time from transplant to death or last follow-up. Rate greater than 0.75 would be considered a success.

Trial Locations

Locations (1)

Memorial SloanKettering Cancer Center; 🇺🇸 New York, New York, United States